Literature DB >> 34313407

MiR-let-7i inhibits CD4+ T cell apoptosis in patients with acute coronary syndrome.

Boxin Zhao1, Zhiyong Zhang1, Lin Gui1, Yingyu Xiang1, Xueyuan Sun1, Lijuan Huang1.   

Abstract

BACKGROUND: Abnormal CD4+ T cells appear in the peripheral blood of patients with acute coronary syndrome (ACS). Studies have confirmed that CD4+ T cells are resistant to apoptosis, but the specific mechanism has not been elucidated yet.
OBJECTIVES: The microRNA (miR)-let-7i plays an important regulatory role in the cardiovascular system and is widely involved in cell proliferation and apoptosis. In this study, we aimed to investigate its functional and regulatory roles in CD4+ T cell apoptosis.
MATERIAL AND METHODS: Apoptosis of CD4+ T cells was detected using TUNEL assay. Western blot analyses were used to detect the expression of Bcl-2 and Bax. Real-time polymerase chain reaction and western blot analyses were used to detect the expression of miR-let-7i, Fas and FasL. A miR-let-7i mimic or inhibitor was transfected into CD4+ T cells, and miR-let-7i activity was investigated using Cell Counting Kit-8 (CCK-8) and TUNEL assays.
RESULTS: Apoptosis of CD4+ T cells in ACS patients was significantly decreased. Overexpression of miR-let-7i inhibited CD4+ T cell apoptosis and improved cell survival rates, while inhibition of miR-let-7i facilitated cell apoptosis. We also found that miR-let-7i negatively regulated Fas and FasL gene expression in CD4+ T cells.
CONCLUSIONS: The present study identified that miR-let-7i significantly reduces Fas and FasL expression in ACS CD4+ T cells and inhibits apoptosis in these cells. Therefore, miR-let-7i may serve as a possible therapeutic target for the treatment of ACS.

Entities:  

Keywords:  CD4+ T cell; Fas; FasL; apoptosis; miR-let-7i

Year:  2021        PMID: 34313407     DOI: 10.17219/acem/135937

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  1 in total

Review 1.  Molecular basis of acute coronary syndrome.

Authors:  Natalya Balashkevich; Maxut Kazymov; Marat Syzdykbayev; Aima Adylova
Journal:  J Res Med Sci       Date:  2022-05-30       Impact factor: 1.985

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.